368703.fig.001
Figure 1: Nonglycemic actions of DPP-4 inhibitor in relation with pathophysiology of CV disease. Despite its many salutary effects on the CV system, DPP-4 inhibitor therapy in patients with type 2 diabetes and CV disease did not show a secondary prevention effect. Some unfavorable actions of DPP-4 inhibitor need to be further characterized to improve DPP-4 inhibitor therapy in patients with type 2 diabetes. ACEi, ACE inhibitor.